14-day Premium Trial Subscription Sign Up For FreeGet Free

Arbutus Biopharma Corporation Stock Forecast NASDAQ:ABUS

$4.14 (4.55%)

Volume: 8M

Closed: Dec 08, 2021

Hollow Logo Score: 0.704

Arbutus Biopharma Corporation Stock Forecast

$4.14 (4.55%)

Volume: 8M

Closed: Dec 08, 2021

Score Hollow Logo 0.704
Which way will ABUS go? Request
Stop-loss: $4.01 (-3.24%)
Key Stats
P/E Ratio -6.18
Beta 0.62
* StockInvest.us uses dynamically calculated RSI max/min levels to determine when stock is oversold or overbought based on historical behavior.
RSImin/max Values: [ 25 - 75 ] RSI14 is 63 and the stock is currently not being overbought or oversold

High volatility in Arbutus Biopharma Corporation stock price on Wednesday which ended trading at $4.14
(Updated on Dec 08, 2021)

Buy or Hold candidate since 2021-12-01 Loss -10.20%

The Arbutus Biopharma Corporation stock price gained 4.55% on the last trading day (Wednesday, 8th Dec 2021), rising from $3.96 to $4.14. , and has now gained 3 days in a row. It will be exciting to see whether it manages to continue gaining or take a minor break for the next few days. During the day the stock fluctuated 11.23% from a day low at $3.83 to a day high of $4.26. The price has risen in 6 of the last 10 days and is up by 32.69% over the past 2 weeks. Volume fell on the last day by -12 million shares and in total, 8 million shares were bought and sold for approximately $32.48 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and falling trend in the short term and further fall within the trend is signaled. Given the current short-term trend, the stock is expected to fall -17.44% during the next 3 months and, with a 90% probability hold a price between $2.43 and $3.74 at the end of this 3-month period. Do note, that if the stock price manages to stay at current levels or higher, our prediction target will start to change positively over the next few days as the conditions for the current predictions will be broken.

Signals & Forecast

The Arbutus Biopharma Corporation stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock. Also, there is a general buy signal from the relation between the two signals where the short-term average is above the long-term average. On corrections down, there will be some support from the lines at $4.01 and $3.70. A breakdown below any of these levels will issue sell signals. A buy signal was issued from a pivot bottom point on Monday, December 06, 2021, and so far it has risen 11.59%. Further rise is indicated until a new top pivot has been found. Furthermore, there is a buy signal from the 3 month Moving Average Convergence Divergence (MACD). Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely.

Special Signal Notification

Double Top Formation

Double Top Formation A sell signal from a double top formation was found on Wednesday, December 01, 2021 and based on theory for this formation the price should fall by -7.31% to $3.84 within 46 trading days since signal was issued (Friday, February 04, 2022).

Support, Risk & Stop-loss

Arbutus Biopharma Corporation finds support from accumulated volume at $4.10 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.

This stock may move very much during the day (volatility) and with a very large prediction interval from the Bollinger Band this stock is considered to be "very high risk". During the last day, the stock moved $0.43 between high and low, or 11.23%. For the last week, the stock has had a daily average volatility of 14.69%.

Our recommended stop-loss: $4.01 (-3.24%) (This stock has very high daily movements and this gives very high risk. There is a buy signal from a pivot bottom found 2 days ago.)

Is Arbutus Biopharma Corporation stock A Buy?

Arbutus Biopharma Corporation holds several positive signals, but we still don't find these to be enough for a buy candidate. At the current level, it should be considered as a hold candidate (hold or accumulate) in this position whilst awaiting further development.

Current score: 0.704

Predicted Opening Price for Arbutus Biopharma Corporation of Thursday, December 9, 2021

The predicted opening price is based on yesterday's movements between high, low, and the closing price.

Fair opening price December 9, 2021 Current price
$4.08 $4.14 (Overvalued)
Hold/Accumulate Unchanged

Remember To Visit Our YouTube Channel

Analyst Ratings

On Dec 02, 2021 "Chardan Capital" gave "$5.00 - $5.50" rating for ABUS. The price target was set to $4.61.

Volatility and Risk
Daily Average Volatility: 14.69 %
Overall Risk: Very High High Medium Low Very Low
14.69 %
Daily Average Volatility
Overall Risk

Very High
Very Low

Support & Resistance

Resistance: $4.31
Price: $4.14
Support: $4.10

ABUS Insider Trading Show all Trades

Date Action Amount Person Type
Show all Insider Trades

Last 0 transactions
Buy: 0 | Sell: 0 (Shares)

Fibonacci Support & Resistance Levels

Level Price Change
Resistance 4.51 8.86 %
4.34 4.89 %
4.24 2.44 %
Current price: 4.14
Support 3.91 -5.50 %
3.81 -7.95 %
3.65 -11.92 %

Accumulated Volume Support & Resistance Levels

Level Price Chg %
Resistance 4.61 11.35 %
4.38 5.80 %
4.31 4.11 %
Current price 4.14
Support 4.10 -0.97%
3.96 -4.35%
3.71 -10.39%

Click to get the best stock tips daily for free!

About Arbutus Biopharma Corporation

Arbutus Biopharma Arbutus Biopharma Corporation, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of chronic hepatitis B (HBV) infections in Canada and the United States. It also develops a pipeline of products based on RNA interference therapeutics (RNAi). Its lead candidate is ARB-1467, a multi-component RNAi therapeutic product that is designed for the elimination of HBV surface antigen expression in patients chronically i... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 100 000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE